Zeo ScientifiX Names New CMO, Reports Equity Sales
Ticker: ZEOX · Form: 8-K · Filed: Aug 7, 2024 · CIK: 1557376
Sentiment: neutral
Topics: executive-change, equity-sale
TL;DR
Zeo ScientifiX swapped CMOs and sold some stock.
AI Summary
Zeo ScientifiX, Inc. announced on July 11, 2024, the resignation of Dr. Robert J. Simon as Chief Medical Officer and the appointment of Dr. David L. Smith as the new Chief Medical Officer. The company also reported on unregistered sales of equity securities.
Why It Matters
A change in key executive leadership like the Chief Medical Officer can signal shifts in the company's strategic direction or operational focus, while unregistered equity sales may indicate financing activities.
Risk Assessment
Risk Level: medium — Changes in executive leadership and unregistered equity sales can introduce uncertainty regarding future performance and strategic execution.
Key Players & Entities
- Zeo ScientifiX, Inc. (company) — Registrant
- Dr. Robert J. Simon (person) — Resigning Chief Medical Officer
- Dr. David L. Smith (person) — Appointed Chief Medical Officer
- July 11, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer for Zeo ScientifiX, Inc.?
Dr. David L. Smith has been appointed as the new Chief Medical Officer for Zeo ScientifiX, Inc.
Who previously held the position of Chief Medical Officer at Zeo ScientifiX, Inc.?
Dr. Robert J. Simon previously held the position of Chief Medical Officer at Zeo ScientifiX, Inc.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is July 11, 2024.
What other item is reported in this 8-K filing besides the executive changes?
The filing also reports on unregistered sales of equity securities.
In which state is Zeo ScientifiX, Inc. incorporated?
Zeo ScientifiX, Inc. is incorporated in Nevada.
Filing Stats: 736 words · 3 min read · ~2 pages · Grade level 12.1 · Accepted 2024-08-07 16:49:46
Key Financial Figures
- $2.35 — e date of grant at an exercise price of $2.35 per share (subject to adjustment for st
Filing Documents
- zeoscientifix_8k.htm (8-K) — 38KB
- 0001829126-24-005286.txt ( ) — 202KB
- ocel-20240711.xsd (EX-101.SCH) — 3KB
- ocel-20240711_lab.xml (EX-101.LAB) — 33KB
- ocel-20240711_pre.xml (EX-101.PRE) — 22KB
- zeoscientifix_8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 7, 2024 ZEO SCIENTIFIX, INC. By: /s/ Ian T. Bothwell Ian T. Bothwell, Interim Chief Executive Officer and Chief Financial Officer 2